Researchers from Alfred Hospital Report New Studies and Findings in the Area of Waldenstrom Macroglobulinemia (Biomarker Analysis of the Aspen Study Comparing Zanubrutinib With Ibrutinib for Patients With Waldenstrom Macroglobulinemia).

Researchers from Alfred Hospital in Melbourne, Australia have conducted a biomarker analysis of the ASPEN study, comparing the efficacy of zanubrutinib and ibrutinib in patients with Waldenstrom Macroglobulinemia (WM). The study found that patients with mutations in CXCR4 and TP53 had worse prognosis compared to those with wild-type alleles, and zanubrutinib led to better clinical outcomes. The research highlights the potential of biomarker analysis in guiding treatment decisions for WM patients. [Extracted from the article]